Trial Profile
A phase 2 study of HKI-272 [neratinib] in subjects with advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Neratinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 May 2012 Company (Puma Biotechnology) added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jun 2010 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.